kynurenic acid has been researched along with Depressive Disorder, Major in 33 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evidence, largely obtained from peripheral studies, suggests that alterations in the kynurenine pathway contribute to the aetiology of depression and disorders involving psychosis." | 8.12 | Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. ( Brown, AM; Brown, SJ; Huang, XF; Newell, KA; Purves-Tyson, TD; Shannon Weickert, C, 2022) |
| "To investigate the relationship between the tryptophan-kynurenine (TRP-KYN) pathway and painful physical symptoms (PPS) in major depressive disorder (MDD)." | 8.12 | Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder. ( An, H; Bai, L; Fan, H; Ma, B; Ma, T; Qi, S; Wang, Z; Yang, F; Yun, Y; Zhang, Q; Zhao, W, 2022) |
| "Tryptophan catabolites ("TRYCATs") produced by the kynurenine pathway (KP) may play a role in depression pathophysiology." | 8.02 | The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation. ( Allers, KA; Beekman, ATF; Giltay, EJ; Keller, S; Milaneschi, Y; Niessen, HG; Penninx, BWJH; Schoevers, RA; Süssmuth, SD, 2021) |
| "Considerable data relate major depressive disorder (MDD) with aberrant immune system functioning." | 5.72 | Peripheral and central kynurenine pathway abnormalities in major depression. ( Asratian, A; Boda, S; Dantzer, R; Erhardt, S; Hamilton, JP; Heilig, M; Holm, L; Kämpe, R; Paul, ER; Samuelsson, M; Schwieler, L; Trepci, A; Yngve, A, 2022) |
| "In schizophrenia and depression, opposite patterns of type-1 - type-2 immune response seem to be associated with differences in the activation of the enzyme indoleamine 2,3-dioxygenase (IDO) and in the tryptophan - kynurenine metabolism resulting in increased production of kynurenic acid in schizophrenia and decreased production of kynurenic acid in depression." | 4.84 | COX-2 inhibition in schizophrenia and major depression. ( Müller, N; Schwarz, MJ, 2008) |
| "Evidence, largely obtained from peripheral studies, suggests that alterations in the kynurenine pathway contribute to the aetiology of depression and disorders involving psychosis." | 4.12 | Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. ( Brown, AM; Brown, SJ; Huang, XF; Newell, KA; Purves-Tyson, TD; Shannon Weickert, C, 2022) |
| "To investigate the relationship between the tryptophan-kynurenine (TRP-KYN) pathway and painful physical symptoms (PPS) in major depressive disorder (MDD)." | 4.12 | Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder. ( An, H; Bai, L; Fan, H; Ma, B; Ma, T; Qi, S; Wang, Z; Yang, F; Yun, Y; Zhang, Q; Zhao, W, 2022) |
| " We evaluated the relationships between total score on the Montgomery-Åsberg Depression Rating Scale and kynurenine, tryptophan, anthranilic acid and kynurenic acid concentrations, IDO activity and tryptophan availability to the brain." | 4.02 | The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin. ( Bugajska, J; Inglot, M; Janocha-Litwin, J; Malyszczak, K; Marciniak, D; Pawlak, D; Pawlowski, T; Zalewska, M, 2021) |
| "Tryptophan catabolites ("TRYCATs") produced by the kynurenine pathway (KP) may play a role in depression pathophysiology." | 4.02 | The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation. ( Allers, KA; Beekman, ATF; Giltay, EJ; Keller, S; Milaneschi, Y; Niessen, HG; Penninx, BWJH; Schoevers, RA; Süssmuth, SD, 2021) |
| " Evidence suggests that the kynurenine (KYN) pathway may be implicated in the pathophysiology of depression, but few studies have explored the association between the KYN pathway and cognitive impairment in MDD." | 3.91 | Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder. ( Chen, L; Li, H; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2019) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Considerable data relate major depressive disorder (MDD) with aberrant immune system functioning." | 1.72 | Peripheral and central kynurenine pathway abnormalities in major depression. ( Asratian, A; Boda, S; Dantzer, R; Erhardt, S; Hamilton, JP; Heilig, M; Holm, L; Kämpe, R; Paul, ER; Samuelsson, M; Schwieler, L; Trepci, A; Yngve, A, 2022) |
| "The kynurenine pathway has been proposed to play a key role between peripheral inflammation and alterations in the central nervous system." | 1.62 | The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder. ( Aydemir, Ö; Kandemir, H; Öztürk, M; Taneli, F; Yalın Sapmaz, Ş, 2021) |
| "The response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including disease severity and inflammation." | 1.56 | The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine. ( Drevets, W; Li, QS; Sun, Y; Turecki, G, 2020) |
| "Kynurenic acid was lower in MDD, and lower levels showed a better therapeutic response to escitalopram." | 1.56 | Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis. ( Erabi, H; Fuchikami, M; Kang, D; Kato, TA; Kurata, A; Okada, G; Okamoto, Y; Setoyama, D; Shibasaki, C; Takamura, M; Yamawaki, S; Yoshino, A, 2020) |
| "Mastocytosis is a rare disease in which chronic symptoms, including depression, are related to mast cell accumulation and activation." | 1.43 | Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. ( Alyanakian, MA; Aouba, A; Bachmeyer, C; Barète, S; Bonin, B; Chandesris, MO; Chauvet-Gelinier, JC; Côté, F; Damaj, G; Dubreuil, P; Gaillard, R; Georgin-Lavialle, S; Grandpeix-Guyodo, C; Haffen, E; Hermine, O; Launay, JM; Lortholary, O; Moura, DS; Salvador, A; Soucié, E; Teyssier, JR; Trojak, B; Vandel, P, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 15 (45.45) | 24.3611 |
| 2020's | 17 (51.52) | 2.80 |
| Authors | Studies |
|---|---|
| Paul, ER | 1 |
| Schwieler, L | 1 |
| Erhardt, S | 1 |
| Boda, S | 1 |
| Trepci, A | 1 |
| Kämpe, R | 1 |
| Asratian, A | 1 |
| Holm, L | 1 |
| Yngve, A | 1 |
| Dantzer, R | 8 |
| Heilig, M | 1 |
| Hamilton, JP | 1 |
| Samuelsson, M | 1 |
| Brown, SJ | 1 |
| Brown, AM | 1 |
| Purves-Tyson, TD | 1 |
| Huang, XF | 1 |
| Shannon Weickert, C | 1 |
| Newell, KA | 1 |
| Wang, L | 1 |
| Yang, P | 1 |
| Yang, C | 1 |
| Yang, D | 1 |
| Wu, X | 1 |
| Cao, T | 1 |
| Zeng, C | 1 |
| Chen, Q | 1 |
| Zhang, S | 1 |
| Zhu, Z | 1 |
| Jiao, S | 1 |
| Cai, H | 1 |
| Zheng, H | 1 |
| Teague, TK | 8 |
| Yeh, FC | 1 |
| Burrows, K | 1 |
| Figueroa-Hall, LK | 1 |
| Aupperle, RL | 1 |
| Khalsa, SS | 1 |
| Paulus, MP | 1 |
| Savitz, J | 7 |
| Almulla, AF | 1 |
| Thipakorn, Y | 1 |
| Vasupanrajit, A | 1 |
| Tunvirachaisakul, C | 1 |
| Oxenkrug, G | 1 |
| Al-Hakeim, HK | 1 |
| Maes, M | 1 |
| Yun, Y | 1 |
| Zhang, Q | 1 |
| Zhao, W | 1 |
| Ma, T | 1 |
| Fan, H | 1 |
| Bai, L | 1 |
| Ma, B | 1 |
| Qi, S | 1 |
| Wang, Z | 1 |
| An, H | 1 |
| Yang, F | 1 |
| Sales, PMG | 3 |
| Schrage, E | 3 |
| Coico, R | 3 |
| Pato, M | 3 |
| Michal, M | 1 |
| Schulz, A | 1 |
| Wild, PS | 1 |
| Koeck, T | 1 |
| Münzel, T | 1 |
| Schuster, AK | 1 |
| Strauch, K | 1 |
| Lackner, K | 1 |
| Süssmuth, SD | 2 |
| Niessen, HG | 2 |
| Borta, A | 1 |
| Allers, KA | 3 |
| Zahn, D | 1 |
| Beutel, ME | 1 |
| Ou, W | 1 |
| Chen, Y | 2 |
| Ju, Y | 1 |
| Ma, M | 1 |
| Qin, Y | 1 |
| Bi, Y | 1 |
| Liao, M | 1 |
| Liu, B | 1 |
| Liu, J | 1 |
| Zhang, Y | 1 |
| Li, L | 1 |
| Olié, E | 1 |
| Lengvenyte, A | 1 |
| Courtet, P | 1 |
| Pu, J | 1 |
| Liu, Y | 1 |
| Zhang, H | 1 |
| Tian, L | 1 |
| Gui, S | 1 |
| Yu, Y | 1 |
| Chen, X | 1 |
| Yang, L | 1 |
| Ran, Y | 1 |
| Zhong, X | 2 |
| Xu, S | 1 |
| Song, X | 1 |
| Liu, L | 1 |
| Zheng, P | 1 |
| Wang, H | 1 |
| Xie, P | 1 |
| Sun, Y | 1 |
| Drevets, W | 1 |
| Turecki, G | 1 |
| Li, QS | 1 |
| Öztürk, M | 1 |
| Yalın Sapmaz, Ş | 1 |
| Kandemir, H | 1 |
| Taneli, F | 1 |
| Aydemir, Ö | 1 |
| Erabi, H | 1 |
| Okada, G | 1 |
| Shibasaki, C | 1 |
| Setoyama, D | 1 |
| Kang, D | 1 |
| Takamura, M | 1 |
| Yoshino, A | 1 |
| Fuchikami, M | 1 |
| Kurata, A | 1 |
| Kato, TA | 1 |
| Yamawaki, S | 1 |
| Okamoto, Y | 1 |
| Marx, W | 1 |
| McGuinness, AJ | 1 |
| Rocks, T | 1 |
| Ruusunen, A | 1 |
| Cleminson, J | 1 |
| Walker, AJ | 1 |
| Gomes-da-Costa, S | 1 |
| Lane, M | 1 |
| Sanches, M | 1 |
| Diaz, AP | 1 |
| Tseng, PT | 1 |
| Lin, PY | 1 |
| Berk, M | 1 |
| Clarke, G | 1 |
| O'Neil, A | 1 |
| Jacka, F | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Quevedo, J | 1 |
| Soares, JC | 1 |
| Fernandes, BS | 1 |
| Pawlowski, T | 1 |
| Pawlak, D | 1 |
| Inglot, M | 1 |
| Zalewska, M | 1 |
| Marciniak, D | 1 |
| Bugajska, J | 1 |
| Janocha-Litwin, J | 1 |
| Malyszczak, K | 1 |
| Milaneschi, Y | 1 |
| Beekman, ATF | 1 |
| Giltay, EJ | 1 |
| Keller, S | 1 |
| Schoevers, RA | 1 |
| Penninx, BWJH | 1 |
| Kim, YK | 1 |
| Won, E | 1 |
| Wurfel, BE | 6 |
| Drevets, WC | 7 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 4 |
| Morris, HM | 3 |
| Savitz, JB | 1 |
| Meier, TB | 3 |
| Mueller, SC | 1 |
| Bodurka, J | 6 |
| DeWitt, SJ | 1 |
| Bradley, KA | 1 |
| Lin, N | 1 |
| Yu, C | 1 |
| Gabbay, V | 1 |
| Wu, Y | 1 |
| Mai, N | 1 |
| Wen, Y | 1 |
| Shang, D | 1 |
| Hu, L | 1 |
| Chen, B | 1 |
| Zhang, M | 1 |
| Ning, Y | 2 |
| Doolin, K | 1 |
| Pleiner, S | 1 |
| Liesener, A | 1 |
| Farrell, C | 1 |
| Tozzi, L | 1 |
| O'Hanlon, E | 1 |
| Roddy, D | 1 |
| Frodl, T | 1 |
| Harkin, A | 1 |
| O'Keane, V | 1 |
| Olajossy, M | 1 |
| Olajossy, B | 1 |
| Potembska, E | 1 |
| Skoczeń, N | 1 |
| Wnuk, S | 1 |
| Urbańska, E | 1 |
| Zhou, Y | 1 |
| Zheng, W | 1 |
| Liu, W | 1 |
| Wang, C | 1 |
| Zhan, Y | 1 |
| Li, H | 1 |
| Chen, L | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 2 |
| Chrétien, F | 1 |
| Gaillard, R | 2 |
| Smith, CM | 1 |
| Victor, TA | 4 |
| Bellgowan, PS | 2 |
| McIntosh, SA | 1 |
| Georgin-Lavialle, S | 1 |
| Moura, DS | 1 |
| Salvador, A | 1 |
| Chauvet-Gelinier, JC | 1 |
| Damaj, G | 1 |
| Côté, F | 1 |
| Soucié, E | 1 |
| Chandesris, MO | 1 |
| Barète, S | 1 |
| Grandpeix-Guyodo, C | 1 |
| Bachmeyer, C | 1 |
| Alyanakian, MA | 1 |
| Aouba, A | 1 |
| Lortholary, O | 1 |
| Dubreuil, P | 1 |
| Teyssier, JR | 1 |
| Trojak, B | 1 |
| Haffen, E | 1 |
| Vandel, P | 1 |
| Bonin, B | 1 |
| Hermine, O | 1 |
| Young, KD | 1 |
| Müller, N | 1 |
| Schwarz, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for kynurenic acid and Depressive Disorder, Major
| Article | Year |
|---|---|
The Tryptophan Catabolite or Kynurenine Pathway in a Major Depressive Episode with Melancholia, Psychotic Features and Suicidal Behaviors: A Systematic Review and Meta-Analysis.
Topics: Albumins; Amino Acids; Depressive Disorder, Major; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2022 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Topics: Biomarkers; Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Quinolinic A | 2023 |
An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Tryptophan | 2021 |
The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Schizophrenia | 2021 |
The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder.
Topics: Animals; Brain; Depressive Disorder, Major; Encephalitis; Humans; Kynurenic Acid; Neurotransmitter A | 2017 |
COX-2 inhibition in schizophrenia and major depression.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Depressive Disorder, Major; Elect | 2008 |
26 other studies available for kynurenic acid and Depressive Disorder, Major
| Article | Year |
|---|---|
Peripheral and central kynurenine pathway abnormalities in major depression.
Topics: Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Quinolinic Acid | 2022 |
Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology.
Topics: Astrocytes; Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Psychotic Di | 2022 |
Disturbance of neurotransmitter metabolism in drug-naïve, first-episode major depressive disorder: a comparative study on adult and adolescent cohorts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Biomarkers; Depressive Disorder, Major; Dopamine; | 2022 |
C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
Topics: C-Reactive Protein; Depressive Disorder, Major; Diffusion Tensor Imaging; Humans; Kynurenic Acid; Ky | 2022 |
Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Pain; Quinolinic Acid; Serotonin; Ta | 2022 |
Tryptophan catabolites and depression in the general population: results from the Gutenberg Health Study.
Topics: Biomarkers; C-Reactive Protein; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Tryp | 2023 |
[How can ketamine be used to manage suicidal risk?]
Topics: Anhedonia; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Hum | 2023 |
The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
Topics: Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Kynurenic Acid; Kynurenine | 2020 |
The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder.
Topics: Adolescent; Cross-Sectional Studies; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; | 2021 |
Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Biomarkers; Case-Control Studies; Citalopram; Depre | 2020 |
The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Depression; Depressive Disorder, Major; Female; He | 2021 |
The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation.
Topics: Depression; Depressive Disorder, Major; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptophan | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
Topics: Adult; Bipolar Disorder; C-Reactive Protein; Contraceptives, Oral, Hormonal; Cross-Sectional Studies | 2018 |
A pilot resting-state functional connectivity study of the kynurenine pathway in adolescents with depression and healthy controls.
Topics: Adolescent; Anhedonia; Brain; Case-Control Studies; Depressive Disorder, Major; Female; Gray Matter; | 2018 |
Kynurenine pathway changes in late-life depression.
Topics: Adult; Age Factors; Aged; Depressive Disorder, Major; Female; Humans; Kynurenic Acid; Kynurenine; Ma | 2018 |
Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Topics: Adult; Biomarkers; C-Reactive Protein; CA1 Region, Hippocampal; CA2 Region, Hippocampal; CA3 Region, | 2018 |
Differences in the dynamics of changes in the concentration of kynurenic acid in the blood serum of depressed patients treated with electroconvulsive therapy.
Topics: Adult; Aged; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Hospitalization; Humans; | 2018 |
Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
Topics: Adult; Chromatography, Liquid; Cognition; Cross-Sectional Studies; Depression; Depressive Disorder, | 2019 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
Topics: Adult; Amygdala; Anhedonia; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Depressive Disord | 2015 |
Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
Topics: Adolescent; Adult; Chromatography, Liquid; Depressive Disorder, Major; Female; Humans; Kynurenic Aci | 2015 |
Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder.
Topics: Adult; Anhedonia; Biomarkers; Corpus Striatum; Depressive Disorder, Major; Female; Humans; Kynurenic | 2015 |
Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Topics: Adult; Brain; C-Reactive Protein; Case-Control Studies; Cerebral Cortex; Depressive Disorder, Major; | 2016 |
Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis.
Topics: Depression; Depressive Disorder, Major; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflam | 2016 |
Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
Topics: Adult; Depressive Disorder, Major; Female; Hippocampus; Humans; Kynurenic Acid; Kynurenine; Magnetic | 2016 |